Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
CARTANA logo — Powering researchers’ insights with innovative single cell,...

CARTANA

Powering researchers’ insights with innovative single cell, spatial biology, & in situ tools. 🧬🔬

Founded 2016 United States Pleasanton, United States 2093 employees IPO Total: $610.90M Biotechnology, Health Care

General Information

Company Name CARTANA
Founded Year 2016
Location United States Pleasanton, United States
Founders / Decision Makers
Team member
Employees 2093
Industries Biotechnology, Health Care
Funding Stage IPO
Business Model B2B, D2C, SaaS
Revenue Model Product Sales, Service Fee, Licensing
Social

BounceWatch is an independent company data service, not affiliated with CARTANA. To contact CARTANA, visit 10xgenomics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About CARTANA

CARTANA, founded in 2016, stands at the forefront of the Biotechnology and Health Care industries in the United States. With its slogan, "Powering researchers’ insights with innovative single cell, spatial biology, & in situ tools," it has carved out a niche in the complex field of cellular research.

The company’s tools are essential for researchers delving into the mysteries of cellular contributions to fields such as oncology, immunology, and neuroscience. Impressively, its technology is cited in over 5,500 publications, highlighting its pivotal role in advancing biological research.

Despite its progress, CARTANA has not seen new investments since its Post IPO Equity funding round on 01 January 2020. Investors might consider this as an opportunity to engage with a company dedicated to unveiling cellular secrets, promising robust growth and innovation in essential scientific arenas.

Taxonomy: Single Cell Analysis, Spatial Biology, In Situ Technology, Oncology Research, Immunology Tools, Neuroscience Insights, DNA Sequencing, Genomic Technology, Scientific Discovery, Innovative Tools, Functional Genomics, Technology Applications, Research Publications, Biologic Insight

Services & Products

Chromium Single Cell Multiomics
Atera In Situ Transcriptomics
Xenium In Situ Imaging
Visium Spatial Analysis

Target Customers

Research Scientists Biotech Companies Pharmaceutical Companies Academic Institutions Clinical Researchers Oncologists Immunologists

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity Undisclosed -
01 Jan 2020
IPO $390.00M -
01 Sep 2019
Late VC $35.00M 3
Verge Fund
Verge Fund, Sophia Genetics +1
01 Jan 2019
Debt Financing $50.00M 5
Paladin Capital Group Wells Fargo Capital Finance
Paladin Capital Group, Wells Fargo Capital Finance +3
01 Apr 2018
Series C $55.00M 5
Venrock Paladin Capital Group Foresite Capital
Venrock, Paladin Capital Group +3
01 Mar 2016
Series B $55.50M 3
Venrock Paladin Capital Group Foresite Capital
Venrock, Paladin Capital Group +1
01 Jan 2015
Series A $22.40M -
01 Nov 2013
Series A $3.00M -
01 Oct 2012

CARTANA Alternatives & Competitors

View All Alternatives
CARTANA vs
Resolve Biosciences
Resolve Biosciences Germany

The Pioneers in Molecular Cartography

Series B
69 employees
Biotechnology, Health Care
CARTANA vs
NanoString Technologies, Inc.
NanoString Technologies, Inc. United States

Mapping the universe of biology 🧬

IPO
225 employees
Biotechnology, Health Care
CARTANA vs
S2 Genomics
S2 Genomics United States

Reimagine your single-cell research with automation.

Acquired
6 employees
Biotechnology, Health Care
View all alternatives

FAQ About CARTANA

Powering researchers’ insights with innovative single cell, spatial biology, & in situ tools. 🧬🔬
CARTANA was founded in 2016.
CARTANA is headquartered in Pleasanton, United States.
CARTANA operates in Biotechnology and Health Care. Its work centres on Single Cell Analysis, Spatial Biology, In Situ Technology and Oncology Research. Its customers include Research Scientists, Biotech Companies and Pharmaceutical Companies.
CARTANA has a B2B, D2C and SaaS business model. Its revenue comes from Product Sales, Service Fee and Licensing.
CARTANA has approximately 2093 employees.
CARTANA has completed 8 funding rounds, raising a total of $610.90M. The latest funding stage is IPO.
CARTANA offers: Chromium Single Cell Multiomics, Atera In Situ Transcriptomics, Xenium In Situ Imaging, Visium Spatial Analysis.
Top alternatives and competitors to CARTANA include Resolve Biosciences, NanoString Technologies, Inc., S2 Genomics, CS Genetics, Mission Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CARTANA and Resolve Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for CARTANA, https://bouncewatch.com/company/cartana, updated 16 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes